Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 7/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.43 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.42 |
| ▸ | CD69 | Q07108 | 1/20 | 0.42 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.41 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.38 |
| ▸ | PTN | P21246 | 1/20 | 0.38 |
| ▸ | MDK | P21741 | 1/20 | 0.38 |
| ▸ | BDNF | P23560 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20216524 | 1.00 | MAPK1 (0.45) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL11989411 | 1.00 | MAPK1 (0.45) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL17072293 | 1.00 | MAPK1 (0.45) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL12213976 | 0.92 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL12085239 | 0.92 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL25121361 | 0.92 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL18254178 | 0.92 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL21374694 | 0.92 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL15215584 | 0.92 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL15082697 | 0.92 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183229-B2 | Bone filling complex and method for fabricating the same | MEGAGEN IMPLANT CO., LTD. (KR) | 2012-05-22 | — | — | US | disclosed |
| US-20100249059-A1 | BONE FILLING COMPLEX AND METHOD FOR FABRICATING THE SAME | MEGAGEN IMPLANT CO., LTD. (KR) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249059-A1 | BONE FILLING COMPLEX AND METHOD FOR FABRICATING THE SAME | BMP2, BMP1, BMP4 | MAPK1 4551/4885LGALS3 1509/4885LGALS8 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.